Stock, Sophia
Fertig, Luisa
Gottschlich, Adrian
Dörr, Janina
Märkl, Florian
Majed, Lina
Menkhoff, Vivien D.
Grünmeier, Ruth
Rejeski, Kai
Cordas dos Santos, David M.
Theurich, Sebastian
von Bergwelt-Baildon, Michael
Endres, Stefan
Subklewe, Marion
Kobold, Sebastian
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung
Deutschen Konsortium für Translationale Krebsforschung
Ludwig-Maximilians-Universität München
SFB-TRR 338
Bavarian Center for Cancer Research
Deutsche Forschungsgemeinschaft
Thomas Kirch Stiftung
Elitenetzwerk Bayern
German Excellence Initiative
Bundesministerium für Bildung und Forschung
Bavarian Elite Graduate Training Network
Wilhelm Sander-Stiftung
Bruno und Helene Jöster Stiftung
Marie Sklodowska-Curie Program Training Network
European Union
Hector Stiftung
Melanoma Research Alliance
Deutsche Krebshilfe
Ernst-Jung-Stiftung
Go-Bio Initiative
Bavarian Ministry for Economical Affairs
European Research Council
Fritz-Bender-Stiftung
Bayerische Forschungsstiftung
José Carreras Leukämie-Stiftung
Universitätsklinik München
Article History
Received: 11 November 2023
Accepted: 22 March 2024
First Online: 17 April 2024
Declarations
:
: SS, LF, AG, JD, FM, LM, VDM, RG, DMCDS and MB have no relevant financial or non-financial interests to disclose relevant for this work. KR received research funding Kite/Gilead, honoraria from BMS/Celgene and Novartis and travel support from Kite/Gilead and Pierre-Fabre. KR serves as a consultant for BMS/Celgene. ST received honoraria from AMGEN, BMS/Celgene, GSK, Janssen, Pfizer, Sanofi, and Takeda. MS received industry research support from Amgen, Bristol-Myers Squibb/Celgene, Gilead, Janssen, Miltenyi Biotec, Morphosys, Novartis, Roche, Seattle Genetics, and Takeda, and serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Molecular Partners, and Takeda. She serves on the speakers’ bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche, and Takeda. SK has received honoraria from TCR2 Inc., Novartis, Galapagos, Cymab, Miltenyi, BMS, and GSK. SK and SE are inventors of several patents in the field of immuno-oncology. SK and SE received license fees from TCR2 Inc. and Carina Biotech. SK and SE received research support from TCR2 Inc., Tabby Therapeutics, Plectonic GmbH, Catalym GmbH, and Arcus Bioscience for work unrelated to the manuscript.
: Approval was obtained from the ethics committee of LMU Munich. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. All animal experimental studies were approved and performed in accordance with guidelines and regulations implemented by the <i>Regierung von Oberbayern</i> (ROB).
: The manuscript does not contain any individual person’s data in any form. No patient consent is necessary for publication.